Oleg E. Akilov, Auris O. Huen, Barbara Pro, Dipenkumar Modi, Ann F. Mohrbacher, Brad M. Haverkos, Aaron R. Mangold, Christiane Querfeld, Ryan A. Wilcox, Louis M. Scarmoutzos, Michael Burns, Earle T. Holsapple, Kenneth D. Massey, Ralph E. Parchment, Yamini Donekal, Ali Moiin
{"title":"一项针对复发/难治性t细胞非霍奇金淋巴瘤的1a/1b期试验,以确定ST-001的安全性、药理学和最大耐受剂量,ST-001是一种静脉注射芬瑞啶脂混悬液(12.5 mg/mL)","authors":"Oleg E. Akilov, Auris O. Huen, Barbara Pro, Dipenkumar Modi, Ann F. Mohrbacher, Brad M. Haverkos, Aaron R. Mangold, Christiane Querfeld, Ryan A. Wilcox, Louis M. Scarmoutzos, Michael Burns, Earle T. Holsapple, Kenneth D. Massey, Ralph E. Parchment, Yamini Donekal, Ali Moiin","doi":"10.1016/j.ejca.2025.115879","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"229 ","pages":""},"PeriodicalIF":7.1000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Phase 1a/1b Trial in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma to Determine the Safety Profile, Pharmacology, and Maximum Tolerated Dose of ST-001, an Intravenous Fenretinide Phospholipid Suspension (12.5 mg/mL)\",\"authors\":\"Oleg E. Akilov, Auris O. Huen, Barbara Pro, Dipenkumar Modi, Ann F. Mohrbacher, Brad M. Haverkos, Aaron R. Mangold, Christiane Querfeld, Ryan A. Wilcox, Louis M. Scarmoutzos, Michael Burns, Earle T. Holsapple, Kenneth D. Massey, Ralph E. Parchment, Yamini Donekal, Ali Moiin\",\"doi\":\"10.1016/j.ejca.2025.115879\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":11980,\"journal\":{\"name\":\"European Journal of Cancer\",\"volume\":\"229 \",\"pages\":\"\"},\"PeriodicalIF\":7.1000,\"publicationDate\":\"2025-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0959804925007087\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0959804925007087","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
A Phase 1a/1b Trial in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma to Determine the Safety Profile, Pharmacology, and Maximum Tolerated Dose of ST-001, an Intravenous Fenretinide Phospholipid Suspension (12.5 mg/mL)
期刊介绍:
The European Journal of Cancer (EJC) serves as a comprehensive platform integrating preclinical, digital, translational, and clinical research across the spectrum of cancer. From epidemiology, carcinogenesis, and biology to groundbreaking innovations in cancer treatment and patient care, the journal covers a wide array of topics. We publish original research, reviews, previews, editorial comments, and correspondence, fostering dialogue and advancement in the fight against cancer. Join us in our mission to drive progress and improve outcomes in cancer research and patient care.